Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

The Toxicities and Adverse Effects That Emergency Physicians Must Know,” published in the December 2024 issue of Emeregency ...

SHR-A1811 showed promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer, ...

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

A University of Liverpool study reveals how two critical molecules present in 'HER2-positive' breast cancer - one of the most ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

The efficacy of trastuzumab deruxtecan after endocrine-based therapy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 is unknown.

台康生技(6589)今(10)日公告乳癌生物相似药EG12014(Trastuzumab Biosimilar, also called EGI2014)FDA药证申覆未通过，查厂结果充填厂仍需改善。台康生技今日股价开盘直接锁在跌停板82.9元，至10:40，超过2800张的卖 ...

Learn about stomach cancer symptoms, causes, and treatments. Understand risk factors and prevention to reduce your chances of ...

A breast cancer drug - which keeps the disease stable for up to four times longer than the previous treatment - will be ...

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...

A remarkable development in breast cancer research has revealed a fundamental mechanism behind driving cancer invasion and ...